Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) EPS (Weighted Average and Diluted) (2019 - 2026)

10x Genomics' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.13 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 68.29% to -$0.13 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.35, a 77.12% increase, with the full-year FY2025 number at -$0.35, up 76.97% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.13 in Q4 2025 for 10x Genomics, up from -$0.22 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TXG hit a ceiling of $0.28 in Q2 2025 and a floor of -$0.79 in Q3 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.3 across 5 years, with a median of -$0.31 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 470.0% in 2022 and later soared 187.5% in 2025.
  • Tracing TXG's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.17 in 2021, then grew by 11.76% to -$0.15 in 2022, then crashed by 173.33% to -$0.41 in 2023, then grew by 0.0% to -$0.41 in 2024, then soared by 68.29% to -$0.13 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TXG at -$0.13 in Q4 2025, -$0.22 in Q3 2025, and $0.28 in Q2 2025.